Cyclosporin A-induced graft-versus-host disease following autologous bone marrow and stem cell transplantation in hematological malignancies of childhood

Bone Marrow Transplantation

Volumn 21, Issue 9, 1998, Pages 901-907

  Gruhn, B ^a   Hafer R ^a   Kosmehl, H ^a   Fuchs, D ^a   Zintl, F ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Bone marrow transplantation; Cyclosporin A; Graft versus host disease; Hematopoietic stem cell transplantation

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD DISEASE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; EPIDERMIS; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; INTRAVENOUS DRUG ADMINISTRATION; MALE; PATHOGENESIS; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SKIN BIOPSY;

EID: 2642611070     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701190     Document Type: Article

References (36)

1. Ringdén O Horowitz MM. Graft-versus-leukemia reactions in humans. Transplant Proc 1989; 21: 2989-2992.
2. Horowitz MM, Gale RP. Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
3. Korngold R, Sprent J. T cell subsets and graft-versus-host disease. Transplantation 1987; 44: 335-339.
4. Champlin R. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation. Hematol Oncol Clin North Am 1990; 4: 687-698.
5. Gale RP, Champlin RE. How does bone-marrow transplantation cure leukaemia? Lancet 1984; 2: 28-30.
6. Kersey JH, Weisdorf D, Nesbit ME et al. Comparison of autologous and allogeneic bone marrow transplantation for treatment of high-risk refractory acute lymphoblastic leukemia. New Engl J Med 1987; 317: 461-467.
7. Hood AF, Vogelsang GB, Black LP et al. Acute graft-vs-host disease: development following autologous and syngeneic bone marrow transplantation. Arch Dermatol 1987; 123: 745-750.
8. Glazier A, Tutschka PJ, Farmer ER, Santos GW. Graft-versus-host disease in cyclosporin A-treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med 1983; 158: 1-8.
9. Bryson JS, Jennings CD, Caywood BE, Kaplan AM. Induction of a syngeneic graft-versus-host disease-like syndrome in DBA/2 mice. Transplantation 1989; 48: 1042-1047.
10. Hess AD, Horwitz L, Beschorner WE, Santos GW. Development of graft-vs-host disease-like syndrome in cyclosporine-treated rats after syngeneic bone marrow transplantation. 1. Development of cytotoxic T lymphocytes with apparent polyclonal anti-Ia specificity, including autoreactivity. J Exp Med 1985; 161: 718-730.
11. Foon KA, Todd RF. Immunologic classification of leukemia and lymphoma. Blood 1986; 68: 1-31.
12. Geller RB, Esa AH, Beschoner WE et al. Successful in vitro graft-versus-tumor effect against an Ia-bearing tumor using cyclosporine-induced syngeneic graft-versus-host disease in the rat. Blood 1989; 74: 1165-1171.
13. Jones RJ. Vogelsang GB, Hess AD et al. Induction ot graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754-757.
14. Carella AM, Gaozza E, Congiu A et al. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation in hematological malignancies. Ann Hematol 1991; 62: 156-159.
15. Talbot DC, Powles RL, Sloane JP et al. Cyclosporine-induced graft-versus-host disease following autologous bone marrow transplantation in acute myeloid leukemia. Bone Marrow Transplant 1990; 6: 17-20.
16. Yeager AM, Vogelsang GB, Jones RJ et al. Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia. Blood 1992; 79: 3031-3035.
17. Yeager AM, Vogelsang GB, Jones RJ et al. Cyclosporine-induced graft-versus-host disease after autologous bone marrow transplantation for acute myeloid leukemia. Leuk Lymphoma 1993; 11: 215-220.
18. Kennedy MJ, Vogelsang GB, Beveridge RA et al. Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1993; 11: 478-484.
19. Pati AR, Godder KT, Abhyankar SH et al. Cyclosporine-induced graft-versus-host disease following autologous blood stem cell transplantation for lymphoma. Bone Marrow Transplant 1996; 17: 1081-1083.
20. Ramsay NKC, Kersey JH, Robison LL et al. A randomized study of the prevention of acute graft-versus-host disease. New Engl J Med 1982; 306: 392-397.
21. Ringdén O, Nilsson B. Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy. Transplantation 1985; 40: 39-44.
22. Lerner KG, Kao GF, Storb R et al. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc 1974; 6: 367-371.
23. Elliott CJ, Sloane JP, Sanderson KV et al. The histological diagnosis of cutaneous graft versus host disease: relationship of skin changes to marrow purging and other clinical variables. Histopathology 1987; 11: 145-155.
24. Snedecor GW, Cochran WG. Statistical Methods. Iowa State University: Ames, 1980, p 135.
25. Fischer AC, Hess AD. Age-related factors in cyclosporine-induced syngeneic graft-versus-host disease: regulatory role of marrow-derived T lymphocytes. J Exp Med 1990; 172: 85-94.
26. Barredo JC, Yusuf U, Hahn A et al. Progressive autologous graft-versus-host disease induced by cyclosporin A. Bone Marrow Transplant 1996; 18: 659-662.
27. Henon PR, Liang H, Beck-Wirth G et al. Comparison of hematopoietic and immune recovery after autologous bone marrow or blood stem cell transplants. Bone Marrow Transplant 1992; 9: 285-291.
28. Ho AD, Maruyama M, Maghazachi A et al. Soluble CD4, soluble CD8, soluble CD25, lymphopoietic recovery, and endogenous cytokines after high-dose chemotherapy and blood stem cell transplantation. Blood 1994; 84: 3550-3557.
29. Sorokin R, Kimura H, Schroder K et al. Cyclosporine-induced autoimmunity: conditions for expressing disease, requirement for intact thymus, and potency estimates of autoimmune lymphocytes in drug-treated rats. J Exp Med 1986; 164: 1615-1625.
30. Bos GMJ, Majoor GD, van Breda Vriesman PJC. Cyclosporin A induces a selective, reversible suppression of T-helper lymphocyte regeneration after syngeneic bone marrow transplantation: association with syngeneic graft-versus-host disease in rats. Clin Exp Immunol 1988; 74: 443-448.
31. Bryson JC, Lake-Bullock H, Pflugh DL et al. In vivo reactivity of T cell clones isolated from mice with syngeneic graft-versus-host disease. Transplantation 1995; 60: 171-178.
32. Hess AD, Bright EC, Thoburn C et al. Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood 1997; 89: 2203-2209.
33. Horn TD, Altomonte V, Vogelsang G, Kennedy MJ. Erythroderma after autologous bone marrow transplantation modified by administration of cyclosporine and interferon gamma for breast cancer. J Am Acad Dermatol 1996; 34: 413-417.
34. Kennedy MJ, Vogelsang GB, Jones RJ et al. Phase I trial of Interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994; 12: 249-257.
35. Ratanatharathorn V, Uberti J, Karanes C et al. Phase I study of alpha-interferon augmentation of cyclosporine-induced graft versus host disease in recipients of autologous bone marrow transplantation. Bone Marrow Transplant 1994; 13: 625-630.
36. Charak BS, Agah R, Mazumder A. Synergism of interleukin-2 and cyclosporine A in induction of a graft-versus-tumor effect without graft-versus-host disease after syngeneic bone marrow transplantation. Blood 1992; 80: 179-184.